In a significant move to drive awareness about precision oncology as an essential, accessible and affordable treatment plan for lung cancer treatment, LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India.
This initiative is backed by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner.
The TARGT First Solid test by 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalized treatment plans based on a patient’s unique genomic profile. This cutting-edge test identifies mutations corresponding to approved therapies by FDA and NCCN (National Comprehensive Cancer Network), empowering oncologists to provide tailored, more effective treatments that can significantly improve patient outcomes.
The primary goal of this initiative is to bridge the gap between innovative cancer care and its accessibility. By offering zero-cost biomarker testing, LuNGS Alliance ensures that financial constraints do not prevent patients from receiving the most advanced cancer treatment available.
According to a study published in The Lancet Regional Health, lung cancer accounts for an estimated 72,510 new cases and 66,279 deaths annually in India. The high mortality rate highlights the urgent need for personalised treatment approaches over the conventional one-size-fits-all methods. Biomarker testing addresses this challenge by offering targeted therapies based on a patient’s unique genetic mutations.
